explore -WSS

explore

author：leisure time 2025-09-07 21:54:10 - browse：6735

Two boxes of Humira and a Humira pen on the side — first opinion coverage from STAT — David J. Phillip/AP

It’s been one year since the launch of the first adalimumab biosimilar for Humira in the United States, which was followed by eight additional adalimumab biosimilar launches. These nine FDA-approved products offer lower-cost alternatives to the world’s bestselling drug, Humira, used to treat rheumatoid arthritis, Crohn’s disease, and other autoimmune disorders. This made 2023 a watershed year for millions of U.S. patients paying too much for their necessary medications.

But so far, that vision hasn’t come to fruition, because policymakers haven’t taken the action necessary to be sure these lower-cost products are accessible for patients. If they fail to act, the U.S. health care system could lose up to $133 billion in savings and leave patients without access to the medicines they need.

Biosimilars are safe and effective treatments referencing biologic drugs. They are market disruptors, forcing lower prices for biologic medicines. The cost savings from reference biologic products begins almost immediately when biosimilars enter the market and continues over time.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Duchenne breakthrough therapy leaves behind pioneering families
Next article： Novo Nordisk touts Wegovy study, but still struggling with supply

focus

WSS

YouTube cracks down on misinformation on cancer treatment

White House finalizes ITC's import ban of latest Apple Watches

Biogen’s boardroom scandal saddles CEO with first crisis

Novo Nordisk touts Wegovy study, but still struggling with supply

Timeline: How the deadly wildfires took over Maui day by day

Treatments for cramps don't cut it. Why aren't there better options?

focus

explore

knowledge

Trump demands the U.S. pay no more for drugs than other countries … again

After Optum profits sink, UnitedHealth makes changes

In age of alternative facts, a scholarly course on calling out crap

Readout Newsletter: Allogene's pivot, Illumina exec to lead Delfi

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Mark Cuban is blaming the wrong people for high drug costs

How one medical school became remarkably diverse

Treatments for cramps don't cut it. Why aren't there better options?

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Mark Cuban is blaming the wrong people for high drug costs

Wikipedia

Hospitals are dialing back on venture capital investing

Illumina slashes 2023 revenue projections yet again

Schizophrenia gene found to be linked to cells' energy dysfunction

Insitro, AI biotech unicorn, brings cash, new research to JPM 2024

Aspartame and sugar

Susan Tousi leaves Illumina to head cancer liquid biopsy startup

focus

knowledge

focus

focus